The Series D comes a little over 18 months after the six-year-old biotech’s third-round financing netted it around $107 million, taking its total raised to date north of $360 million. Ut comes just as FogPharma is preparing to start clinical trials of alpha-helical polypeptide candidate FOG-001.
The lead drug emerging from the biotech’s Helicon platform is billed as a “first-and-only-in-class” direct TCF-blocking beta-catenin inhibitor, which FogPharma says has potential as a treatment for various forms of cancer.
